Targeting IFN-α to B Cell Lymphoma by a Tumor-Specific Antibody Elicits Potent Antitumor Activities
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
IFN-α, a cytokine crucial for the innate immune response, also demonstrates antitumor activity. However, use of IFN-α as an anticancer drug is hampered by its short half-life and toxicity. One approach to improving IFN-α’s therapeutic index is to increase its half-life and tumor localization by fusing it to a tumor-specific Ab. In the present study, we constructed a fusion protein consisting of anti-HER2/neu-IgG3 and IFN-α (anti-HER2/neu-IgG3-IFN-α) and investigated its effect on a murine B cell lymphoma, 38C13, expressing human HER2/neu. Anti-HER2/neu-IgG3-IFN-α exhibited potent inhibition of 38C13/HER2 tumor growth in vivo. Administration of three daily 1-μg doses of anti-HER2/neu-IgG3-IFN-α beginning 1 day after tumor challenge resulted in 88% of the mice remaining tumor free. Remarkably, anti-HER2/neu-IgG3-IFN-α demonstrated potent activity against established 38C13/HER2 tumors, with complete tumor remission observed in 38% of the mice treated with three daily doses of 5 μg of the fusion protein (p = 0.0001). Ab-mediated targeting of IFN-α induced growth arrest and apoptosis of lymphoma cells contributing to the antitumor effect. The fusion protein also had a longer in vivo half-life than rIFN-α. These results suggest that IFN-α Ab fusion proteins may be effective in the treatment of B cell lymphoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meraz, M. A., White, J. M., Sheehan, K. C. F., Bach, E. A., Rodig, S. J., Dighe, A. S., Kaplan, D. H., Riley, J. K., Greenlund, A. C., Campbell, D., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81288-x · Cited by 1,656 · cited 1×
“Although engagement of the IFN- receptor can initiate activation of multiple STAT proteins, STAT1 plays an obligate role in mediating IFN- -dependent signaling (32).”
BackgroundTakaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., et al. (2003) · Nature · doi:10.1038/nature01850 · Cited by 847
Cited by
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Harnessing innate immunity in cancer therapy
Demaria, O., Cornen, S., Daëron, M., Morel, Y., Medzhitov, R., & Vivier, E. (2019) · Nature · doi:10.1038/s41586-019-1593-5 · Cited by 957
Interferons α and β in cancer: therapeutic opportunities from new insights
Borden, E. C. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0011-2 · Cited by 423
Yin and Yang: The dual effects of interferons on hematopoiesis
Demerdash, Y., Kain, B., Essers, M. A. G., & King, K. Y. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.02.002 · Cited by 76
“IFNα was the first IFN and the first cytokine to be produced by the pharmaceutical industry and has been used to treat chronic myeloid leukemia (CML), melanoma, myeloproliferative neoplasms, and chronic Hepatitis B and C infections [1, 14, 15].”
Background
Metadata
- Authors
- Huang, T.-H., Chintalacharuvu, K. R., & Morrison, S. L.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-11
- Volume
- 179
- Issue
- 10
- Pages
- 6881-6888
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2141716239
- Cited by
- 51
- References
- 2
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.